Economic implications of 21-gene recurrence score assay: US multicenter experience

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages

  Hornberger, John ^a,b   Lyman, Gary H ^c   Chien, Rebecca ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cedar Associates LLC   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 GENE RECURRENCE SCORE ASSAY; ASSAY; CANCER CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LETTER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; BREAST TUMOR; CLINICAL TRIAL; COST; ECONOMICS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METHODOLOGY; MULTICENTER STUDY; NOTE; RECURRENT DISEASE; UNITED STATES;

BREAST NEOPLASMS; COSTS AND COST ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; RECURRENCE; UNITED STATES;

EID: 77955915904     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.8944     Document Type: Letter

References (4)

1. Lo S, Norton J, Mumby P, et al: Prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676, 2010
2. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11:313-324, 2005 (Pubitemid 40646936)
3. Lyman G, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018, 2007 (Pubitemid 46435378)
4. Klang SH, Hammerman A, Liebermann N, et al: Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli managed healthcare organization. Value Health (epub ahead of print on April 15, 2010)